The impact of the 2004 NICE guideline and 2003 General Medical Services contract on COPD in primary care in the UK

QJM: An International Journal of Medicine

Volumn 101, Issue 2, 2008, Pages 145-153

  Smith, C J P ^a   Gribbin, J ^a   Challen, K B ^a   Hubbard, Richard B ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID;

ADULT; AGE; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; GENERAL PRACTICE; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; MORTALITY; PRACTICE GUIDELINE; PREDICTION; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SOCIAL STATUS; SPIROMETRY; SURVIVAL RATE; UNITED KINGDOM;

EID: 39049159306     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcm155     Document Type: Article

References (19)

1. The British Thoracic Society. The Burden of Lung Disease: A Statistical Report from the British Thoracic Society. 2nd edn. London, The British Thoracic Society, 2006.
2. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006; 27:188-207.
3. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: Systematic review and meta-analysis. Eur Respir J 2006; 28:523-32.
4. The National Collaborating Centre for Chronic Conditions. Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59(Suppl. 1):i1-i232.
5. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004; 12:171-77.
6. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179-87.
7. Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes J, et al Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000; 55:789-94.
8. Shahab L, Jarvis MJ, Britton J, West R. Prevalence diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 2006; 61:1043-7.
9. de MR, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, et al An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59 120-25.
10. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: Data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000; 160:1683-9.
11. Carey IM, Dewilde S, Harris T, Whincup PH, Cook DG. Spurious trends in coronary heart disease incidence: Unintended consequences of the new GP contract? Br J Gen Pract 2007; 57:486-9.
12. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: Data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58 388-93.
13. Neas LM, Schwartz J. Pulmonary function levels as predictors of mortality in a national sample of US adults. Am J Epidemiol 1998; 147:1011-8.
14. Hole DJ, Watt GC, vey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: Findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313:711-5.
15. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in thronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-89.
16. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A systematic review of randomized placebo-controlled trials. Am J Med 2002; 113 59-65.
17. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2003; 361:449-56.
18. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:912-9.
19. Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. Safety of inhaled corticosteroids. Proc Am Thorac Soc 2004; 1: 171-5.